Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

G. Goss · SciRah

Researcher profile · Semantic Scholar

G. Goss

Share profile

G. Goss — researcher profile on SciRah

h-index: 50
Works: 244
Citations: 13K

Most-cited papers

Apixaban to Prevent Venous Thromboembolism in Patients with Cancer
M. Carrier, K. Abou-Nassar, R. Mallick, V. Tagalakis +19 more
2019New England Journal of Medicine745 citations Open access
Semantic Scholar
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study.
G. Goss, Chun-Ming Tsai, F. Shepherd, L. Bazhenova +16 more
2016The Lancet Oncology592 citations
Semantic Scholar
Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non–Small Cell Lung Cancer
Suzanne Jenkins, J. Yang, S. Ramalingam, Karen Yu +7 more
2017Journal of Thoracic Oncology264 citations Open access
Semantic Scholar
Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study.
M. Tammemagi, H. Schmidt, S. Martel, A. Mcwilliams +44 more
2017The Lancet Oncology188 citations
Semantic Scholar
Safety, Efficacy, and Patient-reported Health-related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including Patients Aged ≥70 Years or with Poor Performance Status (CheckMate 153).
D. Spigel, M. McCleod, R. Jotte, L. Einhorn +17 more
2019Journal of Thoracic Oncology176 citations Open access
Semantic Scholar
Osimertinib in patients with T790M mutation‐positive, advanced non–small cell lung cancer: Long‐term follow‐up from a pooled analysis of 2 phase 2 studies
M. Ahn, Chun-Ming Tsai, F. Shepherd, L. Bazhenova +9 more
2018Cancer149 citations Open access
Semantic Scholar
The Cost‐Effectiveness of High‐Risk Lung Cancer Screening and Drivers of Program Efficiency
S. Cressman, S. Peacock, M. Tammemagi, W. Evans +35 more
2017Journal of Thoracic Oncology134 citations Open access
Semantic Scholar
1297ORandomized results of fixed-duration (1-yr) vs continuous nivolumab in patients (pts) with advanced non-small cell lung cancer (NSCLC)
D. Spigel, M. McLeod, M. Hussein, D. Waterhouse +16 more
201781 citations Open access
Semantic Scholar
Third-generation epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.
Natalie M. Andrews Wright, G. Goss
2019Translational Lung Cancer Research75 citations Open access
Semantic Scholar
P03.03 MERMAID-1: A Phase III Study of Adjuvant Durvalumab plus Chemotherapy in Resected NSCLC Patients with MRD+ Post-Surgery
S. Peters, D. Spigel, M. Ahn, M. Tsuboi +9 more
202156 citations Open access
Semantic Scholar
Efficacy and safety results of depatuxizumab mafodotin (ABT‐414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor
G. Goss, E. Vokes, M. Gordon, L. Gandhi +15 more
2018Cancer56 citations Open access
Semantic Scholar
Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial
G. Goss, E. Felip, M. Cobo, Shun Lu +19 more
2018JAMA Oncology54 citations Open access
Semantic Scholar
Vulvar Squamous Cell Carcinoma (VSCC) as Two Diseases: HPV Status Identifies Distinct Mutational Profiles Including Oncogenic Fibroblast Growth Factor Receptor 3
J. Weberpals, B. Lo, M. Duciaume, J. Spaans +4 more
2017Clinical Cancer Research54 citations
Semantic Scholar
Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non–Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
A. Zer, K. Ding, S. Lee, G. Goss +8 more
2016Journal of Thoracic Oncology53 citations Open access
Semantic Scholar
Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy.
P. Bradbury, D. Morris, G. Nicholas, D. Tu +21 more
2018Lung Cancer51 citations
Semantic Scholar
Health-related quality of life and anxiety in the PAN-CAN lung cancer screening cohort
N. Taghizadeh, A. Tremblay, S. Cressman, S. Peacock +15 more
2019BMJ Open48 citations Open access
Semantic Scholar
Palliative systemic therapy for advanced non-small cell lung cancer: Investigating disparities between patients who are treated versus those who are not.
S. Brule, K. Al-Baimani, H. Jonker, Ting-Hua Zhang +4 more
2016Lung Cancer44 citations
Semantic Scholar
Are clinical trial eligibility criteria an accurate reflection of a real-world population of advanced non-small-cell lung cancer patients?
K. Al-Baimani, H. Jonker, Ting-Hua Zhang, G. Goss +3 more
2018Current Oncology41 citations Open access
Semantic Scholar
Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer
Grant A. Howe, Bin Xiao, Huijun Zhao, K. Al-Zahrani +7 more
2016PLoS ONE40 citations Open access
Semantic Scholar
Evaluation of the VeriStrat® serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study.
S. Gadgeel, G. Goss, J. Soria, E. Felip +15 more
2017Lung Cancer39 citations Open access
Semantic Scholar
CCTG BR34: A randomized phase II trial of durvalumab and tremelimumab +/- platinum-based chemotherapy in patients with metastatic non-small cell lung cancer.
N. Leighl, S. Laurie, G. Goss, B. Hughes +17 more
2021Journal of Thoracic Oncology35 citations Open access
Semantic Scholar
Symptom and Quality of Life Improvement in LUX‐Lung 8, an Open‐Label Phase III Study of Second‐Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First‐Line Platinum‐Based Chemotherapy
E. Felip, V. Hirsh, S. Popat, M. Cobo +12 more
2018Clinical Lung Cancer35 citations Open access
Semantic Scholar
3083 AZD9291 activity in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) and brain metastases: Data from Phase II studies
M. Ahn, Chun-Ming Tsai, J. Yang, F. Shepherd +11 more
201534 citations
Semantic Scholar
A Phase II Study of PF‐03446962 in Patients with Advanced Malignant Pleural Mesothelioma. CCTG Trial IND.207
P. Wheatley-Price, Q. Chu, M. Bonomi, J. Seely +10 more
2016Journal of Thoracic Oncology33 citations Open access
Semantic Scholar
Risk Perception Among a Lung Cancer Screening Population.
J. Turner, G. Pond, A. Tremblay, M. Johnston +12 more
2021Chest32 citations Open access
Semantic Scholar
A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND.196
N. Leighl, M. Tsao, Geoffrey Liu, D. Tu +12 more
2017OncoTarget32 citations Open access
Semantic Scholar
A phase I study of high-dose rosuvastatin with standard dose erlotinib in patients with advanced solid malignancies
G. Goss, D. Jonker, S. Laurie, J. Weberpals +4 more
2016Journal of Translational Medicine31 citations Open access
Semantic Scholar
The Impact of Baseline Edmonton Symptom Assessment Scale Scores on Treatment and Survival in Patients With Advanced Non–small‐cell Lung Cancer
S. McGee, Ting-Hua Zhang, H. Jonker, S. Laurie +4 more
2018Clinical Lung Cancer29 citations
Semantic Scholar
Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: A randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219.
B. Melosky, P. Bradbury, D. Tu, M. Florescu +21 more
2019Lung Cancer28 citations
Semantic Scholar
miR Profiling Identifies Cyclin-Dependent Kinase 6 Downregulation as a Potential Mechanism of Acquired Cisplatin Resistance in Non-Small-Cell Lung Carcinoma.
J. Bar, I. Gorn-Hondermann, P. Moretto, T. Perkins +4 more
2015Clinical Lung Cancer28 citations
Semantic Scholar
Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the Lung.
G. Goss, J. Spaans
2016The Oncologist26 citations Open access
Semantic Scholar
MA16.11 CNS Response to Osimertinib in Patients with T790M-Positive Advanced NSCLC: Pooled Data from Two Phase II Trials
G. Goss, Chun-Ming Tsai, F. Shepherd, M. Ahn +10 more
201725 citations Open access
Semantic Scholar
CCTG BR.34: A randomized trial of durvalumab and tremelimumab +/- platinum-based chemotherapy in patients with metastatic (Stage IV) squamous or nonsquamous non-small cell lung cancer (NSCLC).
N. Leighl, S. Laurie, G. Goss, B. Hughes +15 more
202024 citations
Semantic Scholar
A phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493), a folate receptor targeted chemotherapeutic agent in humans with advanced solid tumors
P. Peethambaram, L. Hartmann, D. Jonker, M. D. de Jonge +10 more
2015Investigational new drugs24 citations
Semantic Scholar
A phase IB study of durvalumab with or without tremelimumab and platinum-doublet chemotherapy in advanced solid tumours: Canadian Cancer Trials Group Study IND226.
R. Juergens, D. Hao, P. Ellis, D. Tu +23 more
2020Lung Cancer23 citations
Semantic Scholar
1416TiP CodeBreak 200: A phase III multicenter study of sotorasib (AMG 510), a KRAS(G12C) inhibitor, versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC) harboring KRAS p.G12C mutation
M. Reck, A. Spira, B. Besse, J. Wolf +12 more
2020Annals of Oncology20 citations Open access
Semantic Scholar
OA07.08 HUDSON: An Open-Label, Multi-Drug, Biomarker-Directed, Phase II Platform Study in Patients with NSCLC, who Progressed on Anti-PD(L)1 Therapy
B. Besse, M. Awad, P. Forde, Michael Thomas +17 more
202119 citations Open access
Semantic Scholar
Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first‐line platinum chemotherapy in high grade serous ovarian cancer
J. Weberpals, Trevor J Pugh, P. Marco-Casanova, G. Goss +18 more
2021Cancer Medicine18 citations Open access
Semantic Scholar
Chronic obstructive pulmonary disease prevalence and prediction in a high-risk lung cancer screening population
J. Goffin, G. Pond, S. Puksa, A. Tremblay +12 more
2020BMC Pulmonary Medicine18 citations Open access
Semantic Scholar
Afatinib (A) vs erlotinib (E) as second-line therapy of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following platinum-based chemotherapy: Overall survival (OS) analysis from the global phase III trial LUX-Lung 8 (LL8).
J. Soria, E. Felip, M. Cobo, Shun Lu +15 more
201516 citations
Semantic Scholar
A novel, more reliable approach to use of progression-free survival as a predictor of gain in overall survival: The Ottawa PFS Predictive Model.
D. Stewart, D. Bossé, G. Goss, J. Hilton +2 more
2020Critical reviews in oncology/hematology15 citations
Semantic Scholar
Long-term safety of BLP25 liposome vaccine (L-BLP25) in patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC).
C. Butts, H. Anderson, A. Maksymiuk, Dimitrios Vergidis +6 more
2016Journal of Clinical Oncology15 citations
Semantic Scholar
Novel Nanoparticle-Based Cancer Treatment, Effectively Inhibits Lung Metastases and Improves Survival in a Murine Breast Cancer Model
S. Kraus, Raz Khandadash, Raphael Hof, A. Nyska +10 more
2021Frontiers in Oncology11 citations Open access
Semantic Scholar
BRM Promoter Polymorphisms and Survival of Advanced Non-Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 trial
Geoffrey Liu, S. Cuffe, Shermi Y. Liang, A. Azad +20 more
2016Clinical Cancer Research11 citations Open access
Semantic Scholar
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trial
G. Goss, M. Cobo, Shun Lu, K. Syrigos +10 more
2021EClinicalMedicine10 citations Open access
Semantic Scholar
Canadian Cancer Trials Group (CCTG) IND215: A phase Ib study of Selumetinib in patients with untreated advanced or metastatic NSCLC who are receiving standard chemotherapy regimens
J. Goffin, G. Nicholas, M. Mates, Dong-Sheng Tu +14 more
2018Investigational new drugs10 citations
Semantic Scholar
MO01.32 CodeBreaK 200: A Phase 3 Multicenter Study of Sotorasib, a KRAS(G12C) Inhibitor, versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring KRAS p.G12C Mutation
M. Reck, A. Spira, B. Besse, Juergen Wolf +12 more
20219 citations Open access
Semantic Scholar
Inpatients versus outpatients with advanced non-small cell lung cancer: Characteristics and outcomes.
J. Gotfrit, C. Jonker, Ting-Hua Zhang, G. Goss +3 more
2019Cancer Treatment and Research Communications9 citations
Semantic Scholar
ABCC2 polymorphisms and survival in the Princess Margaret cohort study and the NCIC clinical trials group BR.24 trial of platinum-treated advanced stage non-small cell lung cancer patients.
S. Cuffe, A. Azad, Xiao-ping Qiu, Xin Qiu +16 more
2016Cancer Epidemiology9 citations
Semantic Scholar
Angiotensin-Converting Enzyme and Aldosterone Serum Levels as Prognostic and Predictive Biomarkers for Cediranib in NCIC Clinical Trials Group Study BR.24.
J. Bar, K. Ding, Huijun Zhao, Lei Han +7 more
2015Clinical Lung Cancer8 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

G. Nicholas×13
Invite
G. Nicholas — researcher profile on SciRah
S. Laurie×13
Invite
S. Laurie — researcher profile on SciRah
F. Shepherd×12
Invite
F. Shepherd — researcher profile on SciRah
P. Bradbury×12
Invite
P. Bradbury — researcher profile on SciRah

×11

Invite

J. Goffin — researcher profile on SciRah

Invite

N. Leighl — researcher profile on SciRah

Invite

M. Tsao — researcher profile on SciRah

Geoffrey Liu×8

Invite

Geoffrey Liu — researcher profile on SciRah

Invite

L. Seymour — researcher profile on SciRah

P. Wheatley-Price×7

Invite

P. Wheatley-Price — researcher profile on SciRah

M. Cantarini×5

Invite

M. Cantarini — researcher profile on SciRah

T. Mitsudomi×5

Invite

T. Mitsudomi — researcher profile on SciRah